Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model

Archive ouverte

Arkoun, Brahim | Robert, Elie | Boudia, Fabien | Mazzi, Stefania | Dufour, Virginie | Siret, Aurélie | Mammasse, Yasmine | Aid, Zakia | Vieira, Matthieu | Imanci, Aygun | Aglave, Marine | Cambot, Marie | Petermann, Rachel | Souquere, Sylvie | Rameau, Philippe | Catelain, Cyril | Diot, Romain | Tachdjian, Gérard | Hermine, Olivier | Droin, Nathalie | Debili, Najet | Plo, Isabelle | Malinge, Sébastien | Soler, Eric | Raslova, Hana | Mercher, Thomas | Vainchenker, William

Edité par CCSD ; American Society for Clinical Investigation -

International audience. Acute megakaryoblastic leukemia of Down syndrome (DS-AMKL) is a model of clonal evolution from a preleukemic transient myeloproliferative disorder requiring both a trisomy 21 (T21) and a GATA1s mutation to a leukemia driven by additional driver mutations. We modeled the megakaryocyte differentiation defect through stepwise gene editing of GATA1s, SMC3+/–, and MPLW515K, providing 20 different T21 or disomy 21 (D21) induced pluripotent stem cell (iPSC) clones. GATA1s profoundly reshaped iPSC-derived hematopoietic architecture with gradual myeloid-to-megakaryocyte shift and megakaryocyte differentiation alteration upon addition of SMC3 and MPL mutations. Transcriptional, chromatin accessibility, and GATA1-binding data showed alteration of essential megakaryocyte differentiation genes, including NFE2 downregulation that was associated with loss of GATA1s binding and functionally involved in megakaryocyte differentiation blockage. T21 enhanced the proliferative phenotype, reproducing the cellular and molecular abnormalities of DS-AMKL. Our study provides an array of human cell–based models revealing individual contributions of different mutations to DS-AMKL differentiation blockage, a major determinant of leukemic progression.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion